SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Neurocrine Biosciences, Inc. (NBIX) trades at a trailing P/E of 27.5, forward P/E of 21.3. Trailing earnings yield is 3.64%, forward earnings yield 4.70%. PEG 0.66 (Peter Lynch undervalued ≤1.0). Graham Number is $59.48.
Criteria proven by this page:
- VALUE (76/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.66); analyst target implies upside (+32.8%).
- Forward P/E 21.3 (down from trailing 27.5) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.66 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 3.64% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 4.70% as earnings recover.
- Analyst consensus target $173.67 (+32.8% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 88/100 with 7/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
76/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NBIX
Valuation Multiples
P/E (TTM)27.5
Forward P/E21.3
PEG Ratio0.66
Forward PEG0.67
P/B Ratio4.05
P/S Ratio4.64
EV/EBITDA18.0
Per Share Data
EPS (TTM)$4.81
Forward EPS (Est.)$6.15
Book Value / Share$32.69
Revenue / Share$28.75
FCF / Share$7.52
Yields & Fair Value
Earnings Yield3.64%
Forward Earnings Yield4.70%
Dividend Yield0.00%
Graham Number$59.48
SharesGrow IV$320.39 (+144.9%)
Analyst Target$173.67 (+32.8%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
-23.7 |
-0.43 |
10.64 |
223.32 |
- |
| 2017 |
-47.9 |
78.07 |
18.35 |
42.24 |
- |
| 2018 |
322.7 |
-2.84 |
14.17 |
15.10 |
- |
| 2019 |
266.2 |
3.25 |
15.46 |
12.50 |
- |
| 2020 |
21.9 |
0.02 |
7.92 |
8.53 |
- |
| 2021 |
89.9 |
-1.15 |
5.86 |
7.11 |
- |
| 2022 |
74.1 |
1.07 |
6.70 |
7.69 |
- |
| 2023 |
51.6 |
0.87 |
5.77 |
6.82 |
- |
| 2024 |
40.2 |
1.22 |
5.29 |
5.82 |
- |
| 2025 |
29.5 |
0.71 |
4.34 |
4.93 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-1.63 |
$15M |
$-141.09M |
-940.6% |
| 2017 |
$-1.62 |
$161.63M |
$-142.54M |
-88.2% |
| 2018 |
$0.22 |
$451.24M |
$21.11M |
4.7% |
| 2019 |
$0.39 |
$788.1M |
$37M |
4.7% |
| 2020 |
$4.16 |
$1.05B |
$407.3M |
38.9% |
| 2021 |
$0.92 |
$1.13B |
$89.6M |
7.9% |
| 2022 |
$1.56 |
$1.49B |
$154.5M |
10.4% |
| 2023 |
$2.47 |
$1.89B |
$249.7M |
13.2% |
| 2024 |
$3.29 |
$2.36B |
$341.3M |
14.5% |
| 2025 |
$4.67 |
$2.86B |
$478.6M |
16.7% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$5.12 |
$4.72 – $6.18 |
$3.45B |
$3.25B – $3.58B |
14 |
| 2027 |
$8.43 |
$7.34 – $10.50 |
$3.89B |
$3.56B – $4.95B |
13 |
| 2028 |
$11.02 |
$6.08 – $17.43 |
$4.39B |
$4.34B – $4.45B |
17 |
| 2029 |
$10.72 |
$9.70 – $12.92 |
$4.43B |
$4.11B – $5.13B |
13 |
| 2030 |
$12.86 |
$11.64 – $15.51 |
$4.8B |
$4.45B – $5.56B |
7 |
